Skip to Content

Generic Avycaz Availability

Avycaz is a brand name of avibactam/ceftazidime, approved by the FDA in the following formulation(s):

AVYCAZ (avibactam sodium; ceftazidime - powder;iv (infusion))

  • Manufacturer: CEREXA INC
    Approval date: February 25, 2015
    Strength(s): EQ 0.5GM BASE;2GM/VIAL [RLD]

Has a generic version of Avycaz been approved?

No. There is currently no therapeutically equivalent version of Avycaz available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Avycaz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
    Patent 7,112,592
    Issued: September 26, 2006
    Inventor(s): Lampilas; Maxime & Aszodi; Jozsef & Rowlands; David Alan & Fromentin; Claude
    Assignee(s): Aventis Pharma S.A.
    The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: The invention also relates to a process for the preparation of these compounds as well as their use as medicaments, in particular as anti-bacterial agents.
    Patent expiration dates:
    • February 24, 2022
      ✓ 
      Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Heterocyclic compounds as inhibitors of beta-lactamases
    Patent 7,612,087
    Issued: November 3, 2009
    Inventor(s): Aszodi; Jozsef & Fromentin; Claude & Lampilas; Maxime & Rowlands; David Alan
    Assignee(s): Novexel
    This invention discloses and claims methods for inhibiting bacterial β-lactamases and treating bacterial infections by inhibiting bacterial β-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a β-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a β-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed.
    Patent expiration dates:
    • November 12, 2026
      ✓ 
      Drug product
  • Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents
    Patent 8,178,554
    Issued: May 15, 2012
    Inventor(s): Lampilas; Maxime & Aszodi; Jozsef & Rowlands; David Alan & Fromentin; Claude
    The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: The invention also relates to a process for the preparation of these compounds as well as their use as medicaments, in particular as anti-bacterial agents.
    Patent expiration dates:
    • July 24, 2021
      ✓ 
      Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
    Patent 8,471,025
    Issued: June 25, 2013
    The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.
    Patent expiration dates:
    • August 12, 2031
      ✓ 
      Drug substance
  • Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
    Patent 8,835,455
    Issued: September 16, 2014
    The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.
    Patent expiration dates:
    • October 8, 2030
      ✓ 
      Drug product
  • Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
    Patent 8,969,566
    Issued: March 3, 2015
    The present invention relates to compounds and processes for preparing compounds of Formula (I), including compounds such as trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof (e.g., NXL-104).
    Patent expiration dates:
    • June 15, 2032
      ✓ 
      Drug substance

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide